Merck and Lundbeck announced today the discontinuation of their joint development program for gaboxadol, an investigational new medicine for the treatment of insomnia currently in Phase III development.
Data from recently completed clinical studies suggest that the overall clinical profile for gaboxadol in insomnia does not support further development.
More
Data from recently completed clinical studies suggest that the overall clinical profile for gaboxadol in insomnia does not support further development.
More
No comments:
Post a Comment